News | August 04, 2022
Lupin Q1 FY23 consolidated loss drops to Rs. 89.08 Cr
Lupin is the 6th largest company in the Indian Pharmaceutical Market
Lupin is the 6th largest company in the Indian Pharmaceutical Market
The company has reported total income of Rs. 253.42 crores during the period ended June 30, 2022.
The company has reported total income of Rs. 21.73 crores during the period ended June 30, 2022.
The company has reported total income of Rs. 1463.03 crores during the period ended June 30, 2022.
The company has reported total income of Rs. 128.79 crores during the period ended June 30, 2022.
he company has reported total income of Rs. 5478.62 crores during the period ended June 30, 2022.
Torrent Pharmaceuticals has reported total income of Rs. 2377 crores during the period ended June 30, 2022.
GMM Pfaudler has reported total income of Rs. 767.73 crores during the period ended June 30, 2022
This next-generation bivalent COVID-19 vaccine candidate, BNT162b5, consists of RNAs encoding enhanced prefusion spike proteins for the SARS-CoV-2 ancestral strain (wild-type) and an Omicron variant.
Biocon has reported total income of Rs. 2217.4 crores during the period ended June 30, 2022.
Subscribe To Our Newsletter & Stay Updated
